Clinical Trials Browser

Phase 1/2 × sotorasib × Clear all

NCT07012031 2026-03-17

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Phase 1/2 Active not recruiting

713 enrolled 1 FDA

Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT05313009 2025-12-16

Tarlox and Sotorasib in Patients With KRAS G12C Mutations

Phase 1/2 Terminated

5 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT04892017 2025-10-10

A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04720976 2025-04-11

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Phase 1/2 Completed

Other solid neoplasmThoracic

Solid Tumor

NCT04092673 2024-05-21

Zotatifin

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT05180422 2023-10-18

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05251038 2023-05-11

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms